Skip to main content
Premium Trial:

Request an Annual Quote

Agendia, AstraZeneca, NKI Partner to ID Colorectal Cancer Subtypes

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Agendia, AstraZeneca, and the Netherlands Cancer Institute today announced a collaboration to identify specific molecular subtypes of colorectal cancer in order to develop targeted therapies.

As part of the deal, Agendia will provide molecular data, bioinformatics support, and diagnostics expertise to AstraZeneca to define subpopulations within colorectal cancer, which kills about 500,000 people in the US and Europe each year, the partners said.

Further terms of the deal were not disclosed.

Bernard Sixt, CEO and co-founder of Agendia, said in a statement that the collaboration will benefit both direct participants as well as the scientific community by "providing a much greater understanding of the various disease types in the colorectal field." He added that a key feature of the partnership is that it may enable the development of companion diagnostics far more quickly than has been currently possible.

Rene Bernards, professor of molecular carcinogenesis at NKI and co-founder of Agendia, said that he and his colleagues have identified distinct molecular subtypes in colorectal cancer, each responding differently to different therapies. "Along with our new partners, we aim to identify drivers of the oncogenic process in each of these subtypes."

The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.